Serving leading biopharmaceutical companies globally:

Last Updated: December 8, 2019

DrugPatentWatch Database Preview

Canakinumab - Biologic Drug Details

See Plans and Pricing

« Back to Dashboard

Summary for canakinumab

Tradenames:	1
Patents:	23
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for canakinumab

Recent Clinical Trials for canakinumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Charles G. Drake	Early Phase 1
Novartis	Early Phase 1
Foundation to Eradicate Duchenne	Phase 1/Phase 2

See all canakinumab clinical trials

Patent Text Search: US Patents for canakinumab

These patents were identified by searching patent claims

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Novartis Pharms	ILARIS	canakinumab	INJECTABLE; SUBCUTANEOUS	125319	001	2009-06-17	Start Trial	City of Hope (Duarte, CA)	2030-10-08	RX	Orphan	search
Novartis Pharms	ILARIS	canakinumab	INJECTABLE; SUBCUTANEOUS	125319	001	2009-06-17	Start Trial	CONFLUENCE LIFE SCIENCES, INC. (St. Louis, MO)	2039-02-26	RX	Orphan	search
Novartis Pharms	ILARIS	canakinumab	INJECTABLE; SUBCUTANEOUS	125319	001	2009-06-17	Start Trial	SynChem, Inc. (Elk Grove Village, IL)	2032-05-31	RX	Orphan	search
Novartis Pharms	ILARIS	canakinumab	INJECTABLE; SUBCUTANEOUS	125319	001	2009-06-17	Start Trial	kaleo, Inc. (Richmond, VA)	2031-01-26	RX	Orphan	search
Novartis Pharms	ILARIS	canakinumab	INJECTABLE; SUBCUTANEOUS	125319	001	2009-06-17	Start Trial	Zymeworks Inc. (Vancouver, British Columbia, CA)	2030-03-29	RX	Orphan	search
Novartis Pharms	ILARIS	canakinumab	INJECTABLE; SUBCUTANEOUS	125319	001	2009-06-17	Start Trial	CureVac AG (Tubingen, DE)	2032-02-15	RX	Orphan	search
Novartis Pharms	ILARIS	canakinumab	INJECTABLE; SUBCUTANEOUS	125319	001	2009-06-17	Start Trial	SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL)	2033-03-11	RX	Orphan	search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

International Patents for canakinumab

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Mexico	2014009884	Start Trial
China	105531374	Start Trial
Australia	2018202009	Start Trial
South Korea	20150036606	Start Trial
Russian Federation	2016132863	Start Trial
Mexico	358862	Start Trial
Canada	2973213	Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson

Moodys

Mallinckrodt

Baxter

Merck

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.